A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China

AbbVie30 enrolled

Overview

The objective of this study to assess the pharmacokinetics, safety, tolerability and immunogenicity following a single subcutaneous (SC) or intravenous (IV) dose of risankizumab in healthy Chinese participants.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Healthy Volunteers

Interventions

RisankizumabDRUG

Intravenous (IV) Infusion

RisankizumabDRUG

Subcutaneous (SC) Injection

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: \- Body Mass Index (BMI) is \>= 19.0 to \<= 26.0 kg/m2 after rounding to the nearest tenth. BMI is calculated as weight in kg divided by the square of height measured in meters. Exclusion Criteria: \- Previous exposure to any anti-IL-12/23 or anti-IL-23 treatment.

Locations (1)

Shanghai Xuhui Central Hospital /ID# 212830

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Number of Participants with Adverse Events (AE)

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.